





Item 8.01. Other Events.

On March 6, 2017 TG Therapeutics, Inc. issued a press release in which it reported topline results from its Phase 3 GENUINE clinical trial of TG-1101 (ublrituximab) plus ibrutinib in patients with previously treated high risk chronic lymphocytic leukemia (CLL). A copy of the press release is being filed as Exhibit 99.1 and incorporated in this Item by reference.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated March 6, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc.  
(Registrant)

Date: March 6, 2017

By: /s/ Sean A. Power  
Sean A. Power  
Chief Financial Officer



INDEX TO EXHIBITS

Exhibit Number	Description
-------------------	-------------

99.1.	Press Release, dated March 6, 2017
-------	------------------------------------